Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.
Introduction - 00:00
Acquiring Expertise in Cardiometabolic Health - 02:29
Advice for Aspiring Cardiometabolic Health Specialists - 04:09
Practical Aspects of Running a Cardiometabolic Practice - 07:30
Navigating Insurance and Cost Barriers - 08:43
Implementing Effective Systems for Therapy Implementation - 09:22
Practical Tips for Implementing Cardiometabolic Therapies - 20:21
Conclusion and Final Thoughts - 22:54
In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and Steve Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, sit down with Taher Modarressi, MD, a cardiometabolic health specialist, to discuss the practical challenges of integrating cardiometabolic therapies into clinical practice.
Modarressi, who launched and owns a standalone practice in the Princeton, NJ area, shares his perspective on his career, what led to establishing the clinic, and the steps he takes to ensure the successful implementation of new therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, for complex, chronic conditions, including diabetes, obesity, and cardiovascular disease. During the conversation, Modarressi highlights the critical role of insurance coverage, patient assistance programs, and prior authorizations in ensuring patients can access these life-changing therapies.
Modarressi also provides practical tips and nuggets of wisdom on how clinicians can work to streamline the process of helping patients obtain guideline-recommended therapies by working with them to understand insurance formularies, using copay cards, and leveraging tools, like CoverMyMeds, for prior authorizations.
All episodes of Don’t Miss a Beat are available in an audio-only format on Spotify and Apple Podcasts.
Relevant disclosures for Modarressi include Amgen, Novo Nordisk, Abbott Laboratories, and Boston Scientific. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.
